REGENXBIO Q1 net loss widens to $76.7M; delays RGX-202 Duchenne trial initiation to H1 2023

REGENXBIO Inc.

2023-Q1 EPS reported -$1.79 revenue$22,218,000

Net loss of $76.7M ($1.79/sh) vs $50.1M loss ($1.20/sh) in Q1 2021; revenue $22.2M up 17% YoY on Zolgensma royalties.
Cash $764.8M, operational runway into 2025; net loss includes $9.2M non-recurring charge from UPenn license amendment.
RGX-314 pivotal trials for wet AMD on track; BLA submission expected in 2024.
RGX-202 Duchenne trial dosing delayed to H1 2023 due to manufacturing observation; trial prep continues.
cGMP manufacturing facility operational for up to 2000L scale; '5x'25' strategy to advance five AAV therapeutics by 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.